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A B S T R A C T
Purpose
Endometrial cancers have long been divided into estrogen-dependent type I and the less common
clinically aggressive estrogen-independent type II. Little is known about risk factors for type II
tumors because most studies lack sufficient cases to study these much less common tumors
separately. We examined whether so-called classical endometrial cancer risk factors also influence
the risk of type II tumors.
Patients and Methods
Individual-level data from 10 cohort and 14 case-control studies from the Epidemiology of
Endometrial Cancer Consortium were pooled. A total of 14,069 endometrial cancer cases and
35,312 controls were included. We classified endometrioid (n  7,246), adenocarcinoma not
otherwise specified (n  4,830), and adenocarcinoma with squamous differentiation (n  777) as
type I tumors and serous (n  508) and mixed cell (n  346) as type II tumors.
Results
Parity, oral contraceptive use, cigarette smoking, age at menarche, and diabetes were associated
with type I and type II tumors to similar extents. Body mass index, however, had a greater effect
on type I tumors than on type II tumors: odds ratio (OR) per 2 kg/m2 increase was 1.20 (95% CI,
1.19 to 1.21) for type I and 1.12 (95% CI, 1.09 to 1.14) for type II tumors (Pheterogeneity  .0001).
Risk factor patterns for high-grade endometrioid tumors and type II tumors were similar.
Conclusion
The results of this pooled analysis suggest that the two endometrial cancer types share many
common etiologic factors. The etiology of type II tumors may, therefore, not be completely
estrogen independent, as previously believed.
J Clin Oncol 31:2607-2618. © 2013 by American Society of Clinical Oncology
INTRODUCTION
On the basis of differences in histology and
clinical outcomes, endometrial cancers have long
been divided into two types.1-4 Type I tumors
comprise the large majority of endometrial can-
cers, are mostly endometrioid adenocarcinomas,
are associated with unopposed estrogen stimula-
tion, and are often preceded by endometrial hy-
perplasia. Type II tumors are predominantly
serous carcinomas and are commonly described
as estrogen independent, arising in atrophic en-
dometrium and deriving from intraepithelial car-
cinoma, a precancerous lesion. Type II tumors
generally are less well differentiated and have
poorer prognoses than type I tumors, and they
account for a disproportionate number of endo-
metrial cancer deaths (40% of deaths, whereas
they only account for 10% to 20% of cases).5 The
disparate genetic alterations found in type I and
type II tumors suggest that these subtypes may
have distinct etiologies.1,3,6
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Many established risk factors for type I endometrial cancers are
related to an imbalance between estrogen and progesterone expo-
sures, including obesity and the use of unopposed estrogen therapy.
Use of combined oral contraceptives (OCs), which is associated with
progesterone-dominant states, reduces the riskof endometrial cancer.
Other risk factors include nulliparity, earlymenarche, and latemeno-
pause, whereas smoking is associated with reduced risk. Little is
known about risk factors for type II tumors, mainly because most
epidemiologic studies7-12 have lacked enough cases to study these less
common tumors separately.
In this study, we combined individual-level data from 24 epide-
miologic studies participating in the Epidemiology of Endometrial
Cancer Consortium (E2C2)13 and performed a pooled analysis with
854 type II and12,853 type I cases and35,312 controls. TheE2C2 is an
international consortium established to pool data in an effort to iden-
tify endometrial cancer genetic andenvironmental risk factors that are
not addressable in a single study. The large number of cases and
controls in E2C2 allowed us to evaluate risk factors for type II tumors
as well as the associations for specific histologic subtypes.
PATIENTS AND METHODS
Participating Studies
Twenty-four studies (10 cohort and 14 case-control) in the E2C2 with
available type II cases were included in the pooled analysis (Table 1). Cohort
studies were analyzed as nested case-control studies, with up to four controls
randomly selected from the risk set (women with intact uteri and without
endometrial cancer before the index case diagnosis) for each case based on
exact year of birth, date of cohort entry ( 6 months), and other criteria as
appropriate for each individual study (eg, race/ethnicity, study area). The
majority of participants were non-Hispanic white, and the populations were
from the United States, Canada, Europe, and Australia. Three studies (Multi-
ethnicCohort [MEC],HawaiiEndometrialCancerStudy [HAW], andShang-
hai Endometrial Cancer Study [SECS]) included mainly or exclusively
nonwhite populations fromtheUnitedStates orChina. Informedconsentwas
obtained from all study participants as part of the original studies in accor-
dance with the requirements of each study’s institutional review board.
Data Collection
Data, with personal identifiers removed, from individual studies were
received at the E2C2 data coordinating center at Memorial Sloan-Kettering
Cancer Center. Each study provided information regarding tumor character-
istics, demographic variables (age at diagnosis for cases and at interview or
reference date for controls, and race/ethnicity), and risk factors (body weight,
height, age at menarche, parity, menopausal hormone use, OC use, smoking
history, and history of diabetes). These variables were defined and uniformly
recoded in accordance with the E2C2 data dictionary. Risk factor data were
obtained from the baseline questionnaire for all cohort studies except one
(Nurses’Health Study [NHS]) that used information from follow-up cycles in
which indexcaseswerediagnosed. Incase-control studies, risk factordatawere
based on a specific reference date (usually 6 to 12 months before date of
diagnosis for cases and date of interview for controls). Bodymass index (BMI,
in kilograms per square meter) in cohort studies was calculated using self-
reported weight and height at baseline, except for Canadian National Breast
ScreeningStudy (NBSS),whichuseddirectmeasurementofweight andheight
during interview. Weight and height in case-control studies was either ascer-
tained by directmeasurement during interview (Alberta, HAW, SECS, Turin,
and University of Southern California, Los Angeles, Case-Control [USC]) or
was self-reported as of the reference date (Australian National Endometrial
Cancer Study [ANECS], Bay Area Women’s Health Study [BAWHS], Con-
necticut Endometrial Cancer Study [CECS], Estrogen, Diet, Genetics, and
Endometrial Cancer [EDGE], FredHutchinsonCancerResearchCenter [FH-
CRC], Polish Endometrial Cancer Study [PECS], Patient Epidemiologic Data
System [PEDS], US Endometrial Cancer Study [US], and Women’s Insight
and Shared Experience [WISE]).
Data Availability
Data on age, race/ethnicity, BMI, age at menarche, parity, menopausal
hormone use (any type), and OC use were provided by all 24 studies. Data
specifically on menopausal estrogen use were not available in five studies
(Alberta, IowaWomen’s Health Study [IWHS], NBSS, SwedishMammogra-
phy Cohort [SMC], and Turin), and data on menopausal estrogen-progestin
use were not available in seven studies (Alberta, Breast Cancer Detection
Demonstration Project [BCDDP], CECS, IWHS, NBBS, Netherlands Cohort
Study [NCLS], and Turin). Duration and recency of estrogen or estrogen-
progestin use were not provided by the majority of studies. Thus we were
unable to quantify the association of specific types of menopausal hormone
use with tumor subtypes. For purposes of analysis, we classified women age
55yearswhosemenopausal statuswasnotavailable (FHCRC)aspostmeno-
pausal. Smoking history was not available in BAWHS, and information re-
garding pack-years of smokingwas not available in six studies (Alberta, CECS,
FHCRC,National Institutes ofHealthAmericaAssociationofRetiredPersons
Diet andHealth Study [NIH-AARP], Turin, andWISE). A history of diabetes
was not available in five studies (ANECS, BAWHS, NBSS, PEDS, and SMC).
Tumor Histology
Only incident cases of endometrial cancer (primary site codes: C54 and
C55.9)were included in this analysis.Histologydatawereobtainedeither from
cancer registry information, pathology report/medical chart review, or slide
review (Table 1). Nineteen studies (Alberta, ANECS, BAWHS, BCDDP,
CECS, Cancer Prevention Study II [CPS-II], CTS, EDGE, FHCRC, HAW,
IWHS,MEC,NBSS,NCLS,NIH-AARP,PEDS, SMC,US, andUSC)provided
the International Classification ofDiseases forOncology (ICD-O-3) histology
codes for each case. Four studies (PECS, SECS, Turin, and WISE) provided
summary histologic type. One study, NHS, collapsed endometrioid, adeno-
carcinoma not otherwise specified (NOS), and mucinous adenocarcinoma
into one group. Fourteen studies (ANECS, BCDDP, FHCRC, HAW, IWHS,
MEC,NLCS,NIH-AARP, SECS, PECS, PEDS,US,USC, andWISE) provided
tumor grade. Seven major tumor subtypes were analyzed separately: endo-
metrioidadenocarcinoma(ICD-O-3code:8380,8381,8382,8383;n7,246),
adenocarcinoma NOS (8140; n  4,830), adenocarcinoma with squamous
differentiation (8560, 8570; n  777), serous/papillary serous (8441, 8460,
8461; n 508), mixed cell adenocarcinoma (8323; n 346), clear cell (8310;
n  196), and mucinous adenocarcinoma (8480, 8481, 8482; n  166).
Tumors of other histologies were excluded from the present analysis owing to
small numbers of each specific type. We classified endometrioid carcinoma,
adenocarcinoma NOS, and adenocarcinoma with squamous differentiation
(n12,853) as type I tumors.Weclassified serous/papillary serous andmixed
cell adenocarcinoma (n854) as type II tumors.Wealso incorporated tumor
grade in the endometrioid cancer analysis for studies with available grade
informationbecauseprevious reports have shown that high-grade endometri-
oid tumors (grade 3) behave similarly to type II cancers.14,15
Exclusion Criteria
Women were excluded from the analysis for extreme BMI values ( 15
or>50kg/m2)becauseof concerns regarding the reliabilityof thesedataor for
missing data on BMI, parity, age at menarche, OC use, or use of menopausal
hormones (n  3,987). With the exception of the BAWHS, which did not
collectdataonsmoking,women in theother studieswhohadmissing smoking
data were excluded from the analyses (n 797). After these exclusions, 854
type II and 12,853 type I cases and 35,312 controls remained for analysis.
Statistical Methods
We created categories for BMI ( 25, 25 to30, 30 to 35, 35 to 40,
 40 kg/m2), age at menarche ( 11, 11 to 12, 13 to 14, 15 years), parity
(0, 1, 2, 3,  4), OC use (never, ever), menopausal status (pre-, postmeno-
pausal), menopausal hormone use (never, ever), smoking status (never, past,
current,missing [forBAWHS]), pack-years of smoking (never smokers,20,
 20), and a history of diabetes mellitus (no, yes). The associations between
risk factors and tumor subtypeswere estimated by odds ratios (ORs) and 95%
CIs using conditional logistic regression stratified jointly by study, age ( 50,
Setiawan et al
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50 to 55, 55 to 60, 60 to 65, 65 to 70, 70 years), and race/ethnicity
(non-Hispanic white, African American/black, Asian, Hawaiian/Pacific Is-
lander, and other) and adjusted for BMI, age at menarche, parity, OC use,
menopausal status, menopausal hormone use, and smoking status. Tests for
trendwereperformedby entering theordinal values representing categories of
BMI, age at menarche, parity, and pack-years of smoking as continuous
variables in the models. Differences in ORs between tumor types were tested
using case-only logistic regressionmodels. Tominimize residual confounding
owing to menopausal hormone use, we repeated analyses restricted to post-
menopausal women who had never used menopausal hormones. We also
evaluated the risk factor associations by selected elements of study design (ie,
cohort v case-control study and source of histologic data [pathologic review v
registry-based]). All P values were two-sided. Statistical analyses were per-
formed using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Characteristics of endometrial cancer cases, by histologic type, and of
controls are shown in Table 2. Themajority of womenwere white (
77% for each group) and postmenopausal ( 79% for each group).
The mean age at diagnosis was highest among patients with serous
tumors and lowest among those diagnosedwith endometrioid cancer
or adenocarcinoma with squamous differentiation. Cases with these
seven histologic types all had higher average BMI than controls;
among cases, the lowest BMI was observed among patients with se-
rous disease. Compared with controls, cases were less likely to be
parous or to have ever smoked.
We examined the association of each risk factor with the seven
histologic types (Table 3). All factors were associatedwith endometri-
oid tumors and adenocarcinomaNOS in thedirection expectedbased
onthe resultsofprevious research; that is, increasingBMIanddiabetes
were positively associated with risk, whereas increasing age at men-
arche, number of children, use of OCs, smoking, and pack-years of
smoking were inversely associated with risk. The ORs for a 2 kg/m2
increase in BMI for serous, mixed cell, clear-cell, and mucinous ade-
nocarcinomas (ORs ranged from1.10 to1.16)were smaller than those
seen for endometrioid adenocarcinoma or the other type I tumors
(ORs ranged from 1.20 to 1.21). The associations of age at menarche,
parity, OC use, smoking, and diabetes with serous, mixed cell, and
mucinous adenocarcinoma were generally similar to those for the
endometrioid tumors. Clear-cell tumors, however, were similar only
with regard to reduced risk associated with OC use. Unlike for other
histologies, increasing age at menarche and number of children were
not significantly associated with reduced risk of clear-cell tumors,
although numbers were small.
Table 4 shows the associations of endometrial cancer risk factors
with risk of type I and type II tumors. Risk factors for both types were
similar.TheORper2kg/m2 increase inBMIwas1.12 (95%CI, 1.09 to
1.14) for type II tumors, weaker than that for type I tumors (OR 
1.20; 95%CI, 1.19 to 1.21;Pheterogeneity .0001). Increasingparity, age
atmenarche, andpack-years of smokingwere associatedwith reduced
risk of both type II and type I tumors to a similar degree and with
significant trends (Ptrend .0006). Prior OCuse and past and current
smokingwere inversely associatedwith both type II and type I tumors
aswell.Ahistoryof diabeteswaspositively associatedwithboth tumor
types (OR  1.53; 95% CI, 1.19 to 1.95 for type II tumors and
OR  1.27; 95% CI, 1.17 to 1.38 for type I tumors). An analysis
restricted to postmenopausal women who never used menopausal
hormones yielded similar results (Appendix Table A1, online only).
We further examined risk factor associations for endometrioid
tumors by tumor grade (Table 5). Compared with low-grade endo-
metrioid tumors (grade 2, n 3,630), risk factor associations for
high-grade tumors (grade  3, n  519) were different only with
respect to BMI, with a stronger association for low-grade tumors (OR
per 2 kg/m2 1.23; 95%CI, 1.21 to 1.25) than for high-grade tumors
(OR 1.16; 95% CI, 1.12 to 1.20; Pheterogeneity .0001). Risk factor
associations for high-grade endometrioid and type II tumorswerenot
different (Pheterogeneity 0.08).
We also examined risk factor associations for type II and type I
tumors by study type and source of histologic data (Appendix Table
A2, online only). The associations were consistent between case-
control and cohort studies and between registry-based studies and
thosewith reviewof pathology reports (or for PECS and SECS, review
of pathology slides).
DISCUSSION
In this large pooled analysis, we observed that most of the classical
endometrial cancer risk factors (ie, obesity, age at menarche, parity,
OCuse, smoking, anddiabetes)were associatedwith the less common
andmore clinically aggressive type II tumors (serous andmixed cell).
In addition, we observed that the risk factor pattern of high-grade
endometrioid tumors and type II tumorswere similar and that the risk
factors for clear-cell tumors seemed to differ from other histologic
types of endometrial cancer.
The first epidemiologic study examining risk factors for specific
endometrial cancer histologic subtypes was a case-control study with
26 serous and 328 endometrioid cancer cases.10 This study found that
BMI, menopausal estrogen use, age at menarche, and parity were
associatedwith endometrioid tumors butnotwith serous tumors.OC
use and smoking were associated with a reduced risk of both tumor
types. The study also found that the age- and BMI-adjusted serum
levels of endogenous estrogen and sex-hormone-binding globulin
(SHBG)were significantly different betweenpatientswith endometri-
oid tumors and patients with serous tumors. Although small in size,
this study raised the possibility that risk factors for serous tumors
might differ from those for endometrioid tumors. Data from this
study coupled with other clinicopathologic and molecular data have
led to the proposed dualistic model of endometrial carcinogenesis.1
Since the initial study, five epidemiologic studies examining risk
factors for type II tumors have been reported,7-9,11,12 with twoof these
studies focusing on BMI.8,9 Similar to our findings, the largest study,8
with 992 type II cases (including papillary, serous, clear cell, and some
poorly differentiated carcinomas), found that BMI was associated
with type II tumors as well as with type I tumors (including endo-
metrioid andmucinous adenocarcinomas) and that themagnitude of
risk was somewhat stronger for type I than type II tumors. However,
the lack of control for potential confounders (ie, parity, exogenous
hormone use, and smoking) in that study left open the possibility of
bias and thus weakened the validity of its finding. The other BMI
study9 had limited statistical power with 70 type II cases, but they also
found BMI to be associated with type II tumors.
The classical endometrial cancer risk factors have been generally
thought to act via estrogenic mechanisms, either by increasing estro-
gen exposure or opposing the effects of estrogen.16 Obesity is associ-
ated with higher levels of circulating estrogens in postmenopausal
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womenandwith lowerprogesterone levels inpremenopausalwomen.
Obesity is also associated with lower levels of SHBG, a protein that
binds and modulates the biologic activity of estrogens. OCs contain
progestins, which directly oppose the effect of estrogen on the endo-
metrium. Smoking reduces estrogen levels by lowering age at meno-
pause and by altering estrogen metabolism.17-20 Hyperinsulinemia, a
common feature of type 2 diabetes, can increase levels of bioactive
estrogens by decreasing SHBG levels.21,22
Type II tumors are commonly described as estrogen indepen-
dent, and thus it might be anticipated that estrogenic and antiestro-
genic exposures would not be related to their risk. However, our
pooled analysis identified associations between both estrogenic and
antiestrogenic factors and risk of type II tumors, suggesting either that
risk factor–associated estrogen-driven proliferation is also important
for type II tumors or that associated mechanisms other than those
involving estrogens drive these associations. For example, mecha-
nismsassociatedwithBMI/obesity, suchashyperinsulinemia, chronic
inflammation, or oxidative activity, may be important.23-27 Hyperin-
sulinemia is also a hallmark of type 2 diabetes, which we found to be
associated with type II tumors independent of BMI. Cigarette smok-
ing has been shown to increase progesterone receptor (PGR) and
homeobox A10 (HOXA10) expression in human endometrium and
Table 4. Association of Endometrial Cancer Risk Factors With Type I and Type II Tumors
Risk Factor
No. of
Controls
Cases
P heterogeneity
Type I Type II†
No. of Cases OR‡ 95% CI No. of Cases OR‡ 95% CI
Mean age at diagnosis, years 12,853 62.7 854 64.8  .0001
Body mass index, kg/m2
 25 18,400 4,602 1.00 330 1.00
25 to  30 10,986 3,718 1.45 1.37 to 1.53 253 1.16 0.98 to 1.38
30 to  35 4,078 2,294 2.52 2.35 to 2.69 159 1.73 1.40 to 2.12
35 to  40 1,255 1,247 4.45 4.05 to 4.89 65 2.15 1.60 to 2.88
 40 593 992 7.14 6.33 to 8.06 47 3.11 2.19 to 4.44
P trend  .0001  .0001  .0001
Body mass index, per 2 kg/m2 35,312 12,853 1.20 1.19 to 1.21 854 1.12 1.09 to 1.14  .0001
Age at menarche, years
 11 1,633 844 1.00 68 1.00
11-12 7,332 2,832 0.89 0.80 to 0.99 220 0.67 0.50 to 0.90
13-14 21,563 7,528 0.85 0.77 to 0.94 466 0.62 0.47 to 0.82
 15 4,784 1,649 0.71 0.63 to 0.80 100 0.50 0.35 to 0.70
P trend  .0001 .0002 .11
Parity
0 4,593 2,451 1.00 150 1.00
1 4,528 1,999 0.74 0.68 to 0.81 121 0.84 0.65 to 1.09
2 10,147 3,728 0.67 0.63 to 0.72 250 0.67 0.54 to 0.83
3 12,119 3,686 0.56 0.52 to 0.60 231 0.56 0.45 to 0.70
 4 3925 989 0.40 0.36 to 0.44 102 0.54 0.41 to 0.72
P trend  .0001  .0001 .31
Oral contraceptive use
Never 20,785 8,011 1.00 497 1.00
Ever 14,527 4,842 0.73 0.69 to 0.77 357 0.74 0.62 to 0.89 .17
Cigarette smoking§
Never 18,815 7,692 1.00 532 1.00
Former 10,900 3,648 0.87 0.82 to 0.91 227 0.70 0.59 to 0.83 .11
Current 5,152 1,126 0.64 0.60 to 0.70 80 0.60 0.46 to 0.77 .79
Pack-years of smoking
Never 13,693 5,646 1.00 367 1.00
 20 5,383 1,639 0.86 0.80 to 0.92 106 0.69 0.55 to 0.87
 20 3,594 1,109 0.71 0.65 to 0.77 69 0.68 0.52 to 0.90
P trend  .0001 .0006 .44
Diabetes¶
No 26,575 8,520 1.00 472 1.00
Yes 2,077 1,402 1.27 1.17 to 1.38 104 1.53 1.19 to 1.95 .14
Abbreviation: OR, odds ratio.
Type I included endometrioid adenocarcinoma, adenocarcinoma not otherwise specified, and adenocarcinoma with squamous differentiation.
†Type II included serous and mixed cell adenocarcinoma.
‡Stratified by age, study and race/ethnicity and mutually adjusted for BMI, age at menarche, parity, oral contraceptive use, menopausal status, menopausal
hormone use, and smoking status.
§Based on 23 studies with smoking data.
Based on 18 studies with pack-years of smoking data.
¶Based on 19 studies with diabetes data.
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endometrial cells.28The roleof otherpossiblemechanismsneeds tobe
considered further in endometrial cancer etiology.
The strengths of this study include a large sample size that pro-
vides greater statistical power than most previous studies have with
regard to examining effects for specific histologic types; minimal, if
any, publicationbias as inclusionof an individual study inour analysis
was not dependent onwhether results had been previously published;
and comparability across studies, in thatwe used individual-level data
to standardize definitions andmodeling approaches for the exposures
and potential confounders, which is not possible in meta-analyses
based on published estimates. Nonetheless, variation in exposure as-
sessment in each study is a limitation of pooled analyses. The unavail-
ability ofdetailedmenopausal hormonedata (recency anddurationof
use of specific hormone type) did not allowus to examine this impor-
tant association and is a limitation of our analysis.
The source of histologic information did not seem to influence
our results, but a certain amount ofmisclassification of tumor types is
likely to be present. A central pathologic review that includes staining
with such critical markers as p53 was not possible, and inclusion of
some type I tumorswithin the type II groupmight, partly, account for
the associations observed for type II tumors. Almost all of the com-
mon associations for type I and type II tumors are, however, equally
strong. For our findings to be a result of misclassification of tumor
type, almost all type II tumorswould have to be type I tumors, and the
BMI results would have been the same for the two tumor types. The
BMI associations, however, were clearly statistically different, clearly
supportingdistinct classifications.Pathologistsgenerallyagree that the
primary concern for misclassification is diagnosing low-grade endo-
metrioid tumors at the expense of high-grade tumors29 and that the
misdiagnosisof tumors as serous isunlikely tobe sufficiently common
Table 5. Association of Endometrial Cancer Risk Factors With Endometrioid Tumors by Grade
Risk Factor
Endometrioid Grade 1 and 2 Endometrioid Grade 3
P heterogeneity
Type II
P heterogeneity‡
No. of
Cases OR† 95% CI
No. of
Cases OR† 95% CI
No. of
Cases OR† 95% CI
Body mass index, kg/m2
 25 1,241 1.00 196 1.00 330 1.00
25 to  30 1,101 1.73 1.57 to 1.91 177 1.69 1.36 to 2.09 253 1.16 0.98 to 1.38
30 to  35 673 3.09 2.73 to 3.49 74 2.02 1.51 to 2.69 159 1.73 1.40 to 2.12
35 to  40 362 5.51 4.67 to 6.51 44 4.17 2.89 to 6.03 65 2.15 1.60 to 2.88
 40 253 7.77 6.30 to 9.58 28 4.51 2.81 to 7.26 47 3.11 2.19 to 4.44
P trend  .0001  .0001 .0001  .0001 .34
Body mass index, per 2 kg/m2 3,630 1.23 1.21 to 1.25 519 1.16 1.12 to 1.20  .0001 854 1.12 1.09 to 1.14 .89
Age at menarche, years
 11 219 1.00 40 1.00 68 1.00
11-12 846 0.82 0.67 to 0.99 110 0.62 0.41 to 0.92 220 0.67 0.50 to 0.90
13-14 1,853 0.77 0.64 to 0.93 276 0.67 0.46 to 0.97 466 0.62 0.47 to 0.82
 15 712 0.66 0.53 to 0.81 93 0.61 0.40 to 0.94 100 0.50 0.35 to 0.70
P trend  .0001 0.18 .75 .0002 .58
Parity
0 624 1.00 87 1.00 150 1.00
1 763 0.68 0.59 to 0.79 83 0.73 0.52 to 1.04 121 0.84 0.65 to 1.09
2 1,026 0.65 0.57 to 0.74 136 0.69 0.52 to 0.93 250 0.67 0.54 to 0.83
3 913 0.54 0.48 to 0.62 158 0.70 0.53 to 0.93 231 0.56 0.45 to 0.70
 4 304 0.42 0.35 to 0.50 55 0.57 0.40 to 0.83 102 0.54 0.41 to 0.72
P trend  .0001 .006 .06  .0001 .39
Oral contraceptive use
Never 2,247 1.00 329 1.00 497 1.00
Ever 1,383 0.77 0.69 to 0.85 190 0.59 0.47 to 0.74 .11 357 0.74 0.62 to 0.89 .14
Cigarette smoking
Never 2,494 1.00 322 1.00 532 1.00
Former 886 0.82 0.74 to 0.91 146 0.93 0.75 to 1.16 227 0.70 0.59 to 0.83
Current 250 0.55 0.47 to 0.64 51 0.84 0.61 to 1.15 .06 80 0.60 0.46 to 0.77 .08
Pack-years of smoking
Never 1,822 1.00 196 1.00 367 1.00
 20 320 0.70 0.60 to 0.82 45 1.05 0.72 to 1.53 106 0.69 0.55 to 0.87
 20 184 0.66 0.54 to 0.81 25 0.83 0.52 to 1.32 69 0.68 0.52 to 0.90
P trend  .0001 0.56 .13 .0006 .47
Diabetes
No 2,288 1.00 343 1.00 472 1.00
Yes 465 1.46 1.28 to 1.67 72 1.26 0.94 to 1.69 .15 104 1.53 1.19 to 1.95 .30
Abbreviation: OR, odds ratio.
Based on 14 studies with tumor grade information.
†Stratified by age, study and race/ethnicity and mutually adjusted for BMI, age at menarche, parity, oral contraceptive use, menopausal status, menopausal
hormone use, and smoking status.
‡Comparing type II with endometrioid grade  3.
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to have produced the necessary amount ofmisclassification to explain
the results obtained here. However, it is clear that future studies need
to use pathologic review and molecular diagnostics to accurately de-
fine tumor type.
In summary, this large pooled analysis provides epidemiologic
evidence that in anumberof respects, the risk factorprofiles for type II
and type I tumors are quite similar, suggesting that they share some
commonetiologic pathways.Thinking regarding aggressivehistologic
subtypes of endometrial cancer might be better served by moving
away from the traditional type I versus type II distinction.
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Appendix
Table A1. Association of Endometrial Cancer Risk Factors With Type I and Type II Tumors Among Postmenopausal Women Who Never Used
Menopausal Hormones
Risk Factor
Type I Type II†
P heterogeneityNo. of Cases OR‡ 95% CI No. of Cases OR‡ 95% CI
Body mass index, kg/m2
 25 1,050 1.00 125 1.00
25 to  30 1,256 1.93 1.74 to 2.14 123 1.41 1.08 to 1.85
30 to  35 1,000 4.08 3.63 to 4.60 91 2.40 1.77 to 3.26
35 to  40 577 7.57 6.45 to 8.87 37 3.38 2.23 to 5.14
 40 460 10.64 8.80 to 12.87 26 3.93 2.37 to 6.49
P trend  .0001  .0001  .0001
Body mass index, per 2 kg/m2 4,343 1.28 1.26 to 1.30 402 1.17 1.13 to 1.21  .0001
Age at menarche, years
 11 323 1.00 29 1.00
11-12 1,014 0.80 0.67 to 0.96 114 0.81 0.52 to 1.29
13-14 2,342 0.79 0.66 to 0.94 205 0.69 0.45 to 1.07
 15 664 0.63 0.51 to 0.77 54 0.56 0.33 to 0.93
P trend  .0001 0.01 .30
Parity
0 733 1.00 69 1.00
1 596 0.74 0.63 to 0.86 51 0.77 0.51 to 1.15
2 1,228 0.68 0.60 to 0.78 112 0.65 0.46 to 0.91
3 1,334 0.57 0.50 to 0.64 110 0.53 0.38 to 0.75
 4 452 0.40 0.34 to 0.47 60 0.50 0.33 to 0.75
P trend  .0001  .0001 .28
Oral contraceptive use
Never 3,091 1.00 266 1.00
Ever 1,252 0.70 0.63 to 0.78 136 0.69 0.52 to 0.92 .25
Cigarette smoking
Never 2,751 1.00 267 1.00
Former 1,144 0.82 0.75 to 0.91 89 0.58 0.45 to 0.76
Current 342 0.60 0.52 to 0.69 39 0.55 0.38 to 0.80 .15
Pack-years of smoking
Never 2,109 1.00 206 1.00
 20 499 0.81 0.70 to 0.93 45 0.55 0.38 to 0.79
 20 386 0.71 0.61 to 0.83 35 0.62 0.42 to 0.92
P trend  .0001 0.002 .33
Diabetes
No 2,670 1.00 199 1.00
Yes 637 1.44 1.27 to 1.64 56 1.63 1.16 to 2.30 .43
Abbreviation: OR, odds ratio.
Type I included endometrioid adenocarcinoma, adenocarcinoma not otherwise specified, and adenocarcinoma with squamous differentiation.
†Type II included serous and mixed cell adenocarcinoma.
‡Stratified by age, study, and race/ethnicity and mutually adjusted for body mass index, age at menarche, parity, oral contraceptive use, and smoking status.
Type I and II Endometrial Cancers: Have They Different Risk Factors?
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